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Background: Sirolimus eluting stent (SES) with biodegradable polymer showed promising results in preliminary studies. This study sought to 
investigate safety and efficacy of SES with biodegradable polymer as compared with SES with durable polymer during one year follow up.
Methods: We undertook a multicentre, open-label, non-inferiority randomized study in 30 centers in China from December 2008 to September 
2010. A total of 1923 patients with de novo coronary artery lesions were randomized to treatment with either SES with biodegradable polymer 
(EXCEL, JW Medical System Ltd, Weihai, China) (n=1242) or SES with durable polymer (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) 
(n=672).The primary endpoint was ischemia-driven target vessel failure (TVF) within 12 months, which was a composite of cardiac death, myocardial 
infarction, and ischemia-driven target vessel revascularization. 
Results: Clinical follow-up at 12 months was available in 96.2% patients. One case (0.15%) of late stent thrombosis occurred in the durable 
polymer SES group. There were no acute and subacute stent thromboses in both groups. During 12 months follow up, SES with biodegradable 
polymer were non-inferior to SES with durable polymer for the primary endpoint (0.32% versus 0.74%, p for noninferiority<0.05, p for 
superiority=0.29). Incidence of cardiac death (0.16% versus 0.30%, p for superiority=0.62), myocardial infarction (0% versus 0.15%, p=0.35), and 
clinically-indicated target vessel revascularization (0.16% versus 0.45%, p=0.35) were similar for both stent types.
Conclusions: Our results suggest that SES with biodegradable polymer is comparable to SES with durable polymer in terms of clinical efficacy and 
safety.
